Research programme: antisense cancer therapeutics - Antisense Pharma

Drug Profile

Research programme: antisense cancer therapeutics - Antisense Pharma

Alternative Names: AP 11014; AP 15000; AP 15012

Latest Information Update: 07 Nov 2013

Price : $50

At a glance

  • Originator Antisense Pharma
  • Developer Isarna Therapeutics
  • Class Antisense oligonucleotides
  • Mechanism of Action Transforming growth factor beta1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 07 Nov 2013 Discontinued - Preclinical for Cancer in Germany (unspecified route)
  • 08 Apr 2004 Data presented at the 95th Annual Meeting of the American Association for Cancer Research (AACR-2004) have been added to the Cancer pharmacodynamics section
  • 04 Jul 2003 Preclinical trials in Cancer in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top